RemeGen Co., Ltd.
92
30
35
28
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
5.4%
5 terminated/withdrawn out of 92 trials
84.8%
-1.7% vs industry average
20%
18 trials in Phase 3/4
0%
0 of 28 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (92)
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Role: collaborator
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Role: collaborator
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Role: lead
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
Role: lead
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
Role: lead
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
Role: lead
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Role: lead
Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease
Role: lead
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
Role: collaborator
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
Role: collaborator
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
Role: lead
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
Role: lead
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
Role: lead
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Role: lead
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Role: lead
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
Role: lead
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
Role: lead
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
Role: lead
A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
Role: lead
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
Role: lead